
Lisaftoclax Granted FDA Clearance for Phase 3 Trial in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Lisaftoclax is a novel, oral, small-molecule, BCL-2 selective inhibitor being evaluated for treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.